search
Back to results

Combination of Telmisartan and Simvastatin in the Treatment of Hypertension and Hypercholesterolemia

Primary Purpose

Hypertension, Dyslipidemias

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
telmisartan
simvastatin
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Willing and able to provide written informed consent Age 18 years or older Hypertension as defined by a mean seated cuff DBP of >=95 - 109 mmHg Hypercholesterolemia as defined by a fasting LDL-C level at visit 2 according to CV risk shown in table below: CV Risk Group: Group I Hypertension and Hypercholesterolemia only Group II Hypertension and Hypercholesterolemia plus > 1 risk factors Group III Hypertension and Hypercholesterolemia plus CHD and/or diabetes mellitus and/or other athero-sclerotic disease Fasting LDL-C group I and II: 100-250 mg/dL (2.6-6.5 mmol/L) Fasting LDL-C group III: 100-160 mg/dL (2.6-4.1 mmol/L) Risk factors: >= 45 yrs if male, >= 55 years if female, family history of CHD, current smoker, HDL-C < 40 mg/dL Exclusion Criteria: pre-menopausal women who are not surgically sterile or are nursing or pregnant or are of child-bearing potential and are not practicing acceptable means of birth control inability to stop current antihypertensive and/or cholesterol-lowering therapies contraindication to a washout/placebo treatment clinically relevant cardiac arrhythmias hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve mean sitting SBP >=180 mmHg or mean sitting DBP >=110 mmHg at two consecutive visits known or suspected secondary hypertension known or suspected secondary hyperlipidemia of any etiology diabetes that has not been stable and controlled for the previous three months severe renal dysfunction bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant or one kidney biliary obstructive disorders, hepatic insufficiency, including past or current liver disease clinically relevant hypokalaemia or hyperkalaemia uncorrected volume depletion uncorrected sodium depletion any history of myopathy or rhabdomyolysis during the past treatment with HMG Co-A reductase inhibitors concurrent use of large quantities of grapefruit juice known hypersensitivity or intolerance to HMG Co-A reductase inhibitors and/or angiotensin receptor blockers, hereditary fructose intolerance planned significant diet and/or lifestyle (including exercise) changes during the treatment phase of the trial history of drug or alcohol dependency any investigational drug therapy within one month of providing informed consent any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of the trial medications

Sites / Locations

  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • ALTI
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Chonnam National University Hospital
  • Hallym University Sacred Heart Hospital
  • Seoul National University Hospital
  • Severance Hospital
  • Korea University Medical Center
  • St. Mary Hospital
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Andromed Breda
  • Gemini Ziekenhuis
  • Andromed Eindhoven
  • Boehringer Ingelheim Investigational Site
  • Andromed Noord
  • Andromed Leiden
  • Andromed Nijmegen
  • Boehringer Ingelheim Investigational Site
  • Andromed Rotterdam
  • Julius Center for Patient oriented Research
  • Andromed Oost
  • Boehringer Ingelheim Investigational Site
  • Andromed Zoetermeer
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Medicinkliniken
  • Medicinkliniken
  • Boehringer Ingelheim Investigational Site
  • Endokrinologkliniken
  • Boehringer Ingelheim Investigational Site
  • Medicinkliniken
  • Boehringer Ingelheim Investigational Site
  • National Cheng Kung University Hospital
  • Mackay Memorial Hospital
  • Chang Gung Memorial Hospital
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site

Outcomes

Primary Outcome Measures

Change in 24-hour ambulatory blood pressure measurement (ABPM) measured mean diastolic blood pressure (DBP)
Change in 24-hour ambulatory blood pressure measurement (ABPM) measured mean low density lipoprotein (LDL)

Secondary Outcome Measures

Change in the 24-hour ABPM (Ambulatory Blood Pressure Monitoring) measured mean SBP
Changes in Trough-to-peak ratios of SBP and DBP, taken from ABPM
Changes in Seated morning DBP and SBP
Response rate to blood pressure treatment
Response rate to lipid lowering treatment
Change in Total cholesterol
Change in HDL-cholesterol
Change in triglycerides
Change in Apolipoprotein B
Change in free fatty acids
Change in Adiponectin
Change in HOMA-index
Change in haemoglobin A1C
Changes in high sensitive c-reactive protein
Changes in microalbuminuria
Adverse events
Changes in clinical laboratory parameter
Assessment of pulse rate

Full Information

First Posted
April 19, 2006
Last Updated
October 31, 2013
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT00316095
Brief Title
Combination of Telmisartan and Simvastatin in the Treatment of Hypertension and Hypercholesterolemia
Official Title
Reduced Factorial Design, Randomized, Double Blind Trial Comparing Combinations of Telmisartan 20 or 80 mg and Simvastatin 20 or 40 mg With Single Component Therapies in the Treatment of Hypertension and Dyslipidemia
Study Type
Interventional

2. Study Status

Record Verification Date
October 2013
Overall Recruitment Status
Completed
Study Start Date
April 2006 (undefined)
Primary Completion Date
August 2007 (Actual)
Study Completion Date
August 2007 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Boehringer Ingelheim

4. Oversight

5. Study Description

Brief Summary
This study will investigate two registered drugs, one for the treatment of high blood pressure and one for the treatment of elevated cholesterol. High blood pressure (hypertension) is a common medical condition affecting millions of people worldwide. A wide variety of effective drug treatments is available to reduce blood pressure. Elevated cholesterol (hypercholesterolemia) is a common medical condition affecting people worldwide. A wide variety of effective drug treatments is available to reduce cholesterol levels. Hypertension and hypercholesterolemia often occur together. They are both important risk factors for the development of heart and vessel diseases (e.g. heart attack or stroke). Current guidelines advise treatment of high blood pressure and elevated cholesterol to reduce the risk of cardiovascular diseases. This study will test the simultaneous use of a drug to reduce blood pressure and a drug to reduce elevated cholesterol. Both drugs are registered and are effective. The drug for treatment of high blood pressure is telmisartan Micardis). The drug for treatment of elevated cholesterol is simvastatin (Zocor). Since hypertension and hypercholesterolemia frequently occur together, the purpose of this study is to investigate whether both drugs can be used simultaneously. A low dose and a high dose of these drugs will be used. It will be investigated whether each of the drugs is still as effective when given together, at the same time of day, with the other drug.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Dyslipidemias

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Factorial Assignment
Masking
Double
Allocation
Randomized
Enrollment
1695 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
telmisartan
Intervention Type
Drug
Intervention Name(s)
simvastatin
Primary Outcome Measure Information:
Title
Change in 24-hour ambulatory blood pressure measurement (ABPM) measured mean diastolic blood pressure (DBP)
Time Frame
8 weeks
Title
Change in 24-hour ambulatory blood pressure measurement (ABPM) measured mean low density lipoprotein (LDL)
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Change in the 24-hour ABPM (Ambulatory Blood Pressure Monitoring) measured mean SBP
Time Frame
after 8 weeks
Title
Changes in Trough-to-peak ratios of SBP and DBP, taken from ABPM
Time Frame
after 8 weeks
Title
Changes in Seated morning DBP and SBP
Time Frame
after 8 weeks
Title
Response rate to blood pressure treatment
Time Frame
after 8 weeks
Title
Response rate to lipid lowering treatment
Time Frame
after 8 weeks
Title
Change in Total cholesterol
Time Frame
after 8 weeks
Title
Change in HDL-cholesterol
Time Frame
after 8 weeks
Title
Change in triglycerides
Time Frame
after 8 weeks
Title
Change in Apolipoprotein B
Time Frame
after 8 weeks
Title
Change in free fatty acids
Time Frame
after 8 weeks
Title
Change in Adiponectin
Time Frame
after 8 weeks
Title
Change in HOMA-index
Time Frame
after 8 weeks
Title
Change in haemoglobin A1C
Time Frame
after 8 weeks
Title
Changes in high sensitive c-reactive protein
Time Frame
after 8 weeks
Title
Changes in microalbuminuria
Time Frame
after 8 weeks
Title
Adverse events
Time Frame
up to 15 weeks
Title
Changes in clinical laboratory parameter
Time Frame
up to 15 weeks
Title
Assessment of pulse rate
Time Frame
up to 15 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Willing and able to provide written informed consent Age 18 years or older Hypertension as defined by a mean seated cuff DBP of >=95 - 109 mmHg Hypercholesterolemia as defined by a fasting LDL-C level at visit 2 according to CV risk shown in table below: CV Risk Group: Group I Hypertension and Hypercholesterolemia only Group II Hypertension and Hypercholesterolemia plus > 1 risk factors Group III Hypertension and Hypercholesterolemia plus CHD and/or diabetes mellitus and/or other athero-sclerotic disease Fasting LDL-C group I and II: 100-250 mg/dL (2.6-6.5 mmol/L) Fasting LDL-C group III: 100-160 mg/dL (2.6-4.1 mmol/L) Risk factors: >= 45 yrs if male, >= 55 years if female, family history of CHD, current smoker, HDL-C < 40 mg/dL Exclusion Criteria: pre-menopausal women who are not surgically sterile or are nursing or pregnant or are of child-bearing potential and are not practicing acceptable means of birth control inability to stop current antihypertensive and/or cholesterol-lowering therapies contraindication to a washout/placebo treatment clinically relevant cardiac arrhythmias hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve mean sitting SBP >=180 mmHg or mean sitting DBP >=110 mmHg at two consecutive visits known or suspected secondary hypertension known or suspected secondary hyperlipidemia of any etiology diabetes that has not been stable and controlled for the previous three months severe renal dysfunction bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant or one kidney biliary obstructive disorders, hepatic insufficiency, including past or current liver disease clinically relevant hypokalaemia or hyperkalaemia uncorrected volume depletion uncorrected sodium depletion any history of myopathy or rhabdomyolysis during the past treatment with HMG Co-A reductase inhibitors concurrent use of large quantities of grapefruit juice known hypersensitivity or intolerance to HMG Co-A reductase inhibitors and/or angiotensin receptor blockers, hereditary fructose intolerance planned significant diet and/or lifestyle (including exercise) changes during the treatment phase of the trial history of drug or alcohol dependency any investigational drug therapy within one month of providing informed consent any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of the trial medications
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim Study Coordinator
Organizational Affiliation
Boehringer Ingelheim BV/Alkmaar
Official's Role
Study Chair
Facility Information:
Facility Name
Boehringer Ingelheim Investigational Site
City
Benatky nad Jizerou
ZIP/Postal Code
294 71
Country
Czech Republic
Facility Name
Boehringer Ingelheim Investigational Site
City
Brno
ZIP/Postal Code
65691
Country
Czech Republic
Facility Name
Boehringer Ingelheim Investigational Site
City
Mlada Boleslav
ZIP/Postal Code
293 01
Country
Czech Republic
Facility Name
Boehringer Ingelheim Investigational Site
City
Plzen
ZIP/Postal Code
301 00
Country
Czech Republic
Facility Name
Boehringer Ingelheim Investigational Site
City
Praha 5
ZIP/Postal Code
158 00
Country
Czech Republic
Facility Name
Boehringer Ingelheim Investigational Site
City
Pribram
ZIP/Postal Code
261 01
Country
Czech Republic
Facility Name
Boehringer Ingelheim Investigational Site
City
Unicov
ZIP/Postal Code
783 91
Country
Czech Republic
Facility Name
Boehringer Ingelheim Investigational Site
City
Usti nad Orlici
ZIP/Postal Code
562 18
Country
Czech Republic
Facility Name
ALTI
City
Angers
ZIP/Postal Code
49000
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Angers
ZIP/Postal Code
49000
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Sidi Daoud Tunis
ZIP/Postal Code
2046
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Tunis
ZIP/Postal Code
1089
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Haag
ZIP/Postal Code
83527
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Mainz
ZIP/Postal Code
55116
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Neuburg a. d. Donau
ZIP/Postal Code
86633
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Nurnberg
ZIP/Postal Code
90402
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Rednitzhembach
ZIP/Postal Code
91126
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Unterschneidheim
ZIP/Postal Code
73485
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Westerkappeln
ZIP/Postal Code
49492
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Wiesbaden
ZIP/Postal Code
65191
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Wurzburg
ZIP/Postal Code
97072
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Hong Kong
Country
Hong Kong
Facility Name
Chonnam National University Hospital
City
Kwangju
ZIP/Postal Code
501757
Country
Korea, Republic of
Facility Name
Hallym University Sacred Heart Hospital
City
Kyunggi-do
ZIP/Postal Code
431070
Country
Korea, Republic of
Facility Name
Seoul National University Hospital
City
Seoul
ZIP/Postal Code
110774
Country
Korea, Republic of
Facility Name
Severance Hospital
City
Seoul
ZIP/Postal Code
120752
Country
Korea, Republic of
Facility Name
Korea University Medical Center
City
Seoul
ZIP/Postal Code
136705
Country
Korea, Republic of
Facility Name
St. Mary Hospital
City
Seoul
ZIP/Postal Code
150713
Country
Korea, Republic of
Facility Name
Boehringer Ingelheim Investigational Site
City
Almere
ZIP/Postal Code
1311RL
Country
Netherlands
Facility Name
Boehringer Ingelheim Investigational Site
City
Beek en Donk
ZIP/Postal Code
5741 CG
Country
Netherlands
Facility Name
Andromed Breda
City
Breda
ZIP/Postal Code
4811 VL
Country
Netherlands
Facility Name
Gemini Ziekenhuis
City
Den Helder
ZIP/Postal Code
1782 GZ
Country
Netherlands
Facility Name
Andromed Eindhoven
City
Eindhoven
ZIP/Postal Code
5611 NJ
Country
Netherlands
Facility Name
Boehringer Ingelheim Investigational Site
City
Ewijk
ZIP/Postal Code
6644 CL
Country
Netherlands
Facility Name
Andromed Noord
City
Groningen
ZIP/Postal Code
9711 SG
Country
Netherlands
Facility Name
Andromed Leiden
City
Leiden
ZIP/Postal Code
2311 GZ
Country
Netherlands
Facility Name
Andromed Nijmegen
City
Nijmegen
ZIP/Postal Code
6533 HL
Country
Netherlands
Facility Name
Boehringer Ingelheim Investigational Site
City
Oude Pekela
ZIP/Postal Code
9665 BJ
Country
Netherlands
Facility Name
Andromed Rotterdam
City
Rotterdam
ZIP/Postal Code
3021 HC
Country
Netherlands
Facility Name
Julius Center for Patient oriented Research
City
Utrecht
ZIP/Postal Code
3584 CJ
Country
Netherlands
Facility Name
Andromed Oost
City
Velp
ZIP/Postal Code
6883 ES
Country
Netherlands
Facility Name
Boehringer Ingelheim Investigational Site
City
Wildervank
ZIP/Postal Code
9648 BE
Country
Netherlands
Facility Name
Andromed Zoetermeer
City
Zoetermeer
ZIP/Postal Code
2724 EK
Country
Netherlands
Facility Name
Boehringer Ingelheim Investigational Site
City
Moscow
ZIP/Postal Code
101990
Country
Russian Federation
Facility Name
Boehringer Ingelheim Investigational Site
City
Moscow
ZIP/Postal Code
117036
Country
Russian Federation
Facility Name
Boehringer Ingelheim Investigational Site
City
Moscow
ZIP/Postal Code
119992
Country
Russian Federation
Facility Name
Boehringer Ingelheim Investigational Site
City
Moscow
ZIP/Postal Code
121356
Country
Russian Federation
Facility Name
Boehringer Ingelheim Investigational Site
City
Moscow
ZIP/Postal Code
121552
Country
Russian Federation
Facility Name
Boehringer Ingelheim Investigational Site
City
Moscow
ZIP/Postal Code
127018
Country
Russian Federation
Facility Name
Boehringer Ingelheim Investigational Site
City
Moscow
ZIP/Postal Code
129010
Country
Russian Federation
Facility Name
Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
Boehringer Ingelheim Investigational Site
City
St. Petersburg
ZIP/Postal Code
195257
Country
Russian Federation
Facility Name
Boehringer Ingelheim Investigational Site
City
St. Petersburg
ZIP/Postal Code
198013
Country
Russian Federation
Facility Name
Boehringer Ingelheim Investigational Site
City
Bratislava
ZIP/Postal Code
82606
Country
Slovakia
Facility Name
Boehringer Ingelheim Investigational Site
City
Kosice
ZIP/Postal Code
040 01
Country
Slovakia
Facility Name
Boehringer Ingelheim Investigational Site
City
Kralovsky Chmlec
ZIP/Postal Code
077 01
Country
Slovakia
Facility Name
Boehringer Ingelheim Investigational Site
City
Liptovsky Hradok
ZIP/Postal Code
033 01
Country
Slovakia
Facility Name
Boehringer Ingelheim Investigational Site
City
Nitra
ZIP/Postal Code
950 01
Country
Slovakia
Facility Name
Boehringer Ingelheim Investigational Site
City
Povazska Bystrica
ZIP/Postal Code
017 01
Country
Slovakia
Facility Name
Boehringer Ingelheim Investigational Site
City
Presov
ZIP/Postal Code
081 81
Country
Slovakia
Facility Name
Boehringer Ingelheim Investigational Site
City
Trencin
ZIP/Postal Code
911 05
Country
Slovakia
Facility Name
Boehringer Ingelheim Investigational Site
City
Vrable
ZIP/Postal Code
952 01
Country
Slovakia
Facility Name
Boehringer Ingelheim Investigational Site
City
Boksburg
ZIP/Postal Code
1461
Country
South Africa
Facility Name
Boehringer Ingelheim Investigational Site
City
Cape Town
ZIP/Postal Code
7405
Country
South Africa
Facility Name
Boehringer Ingelheim Investigational Site
City
Cape Town
ZIP/Postal Code
7925
Country
South Africa
Facility Name
Boehringer Ingelheim Investigational Site
City
Durban
ZIP/Postal Code
4091
Country
South Africa
Facility Name
Boehringer Ingelheim Investigational Site
City
Johannesburg
ZIP/Postal Code
2033
Country
South Africa
Facility Name
Boehringer Ingelheim Investigational Site
City
Krugersdorp
ZIP/Postal Code
1739
Country
South Africa
Facility Name
Boehringer Ingelheim Investigational Site
City
Midrand
ZIP/Postal Code
1685
Country
South Africa
Facility Name
Medicinkliniken
City
Goteborg
ZIP/Postal Code
416 85
Country
Sweden
Facility Name
Medicinkliniken
City
Lule?
ZIP/Postal Code
971 80
Country
Sweden
Facility Name
Boehringer Ingelheim Investigational Site
City
Lule?
ZIP/Postal Code
S-971 31
Country
Sweden
Facility Name
Endokrinologkliniken
City
Malmo
ZIP/Postal Code
205 02
Country
Sweden
Facility Name
Boehringer Ingelheim Investigational Site
City
Rattvik
ZIP/Postal Code
795 33
Country
Sweden
Facility Name
Medicinkliniken
City
Stockholm
ZIP/Postal Code
182 88
Country
Sweden
Facility Name
Boehringer Ingelheim Investigational Site
City
Uppsala
ZIP/Postal Code
S-752 23
Country
Sweden
Facility Name
National Cheng Kung University Hospital
City
Tainan
ZIP/Postal Code
704
Country
Taiwan
Facility Name
Mackay Memorial Hospital
City
Taipei
ZIP/Postal Code
104
Country
Taiwan
Facility Name
Chang Gung Memorial Hospital
City
Taoyuan
ZIP/Postal Code
333
Country
Taiwan
Facility Name
Boehringer Ingelheim Investigational Site
City
Dnepropetrovsk
ZIP/Postal Code
49006
Country
Ukraine
Facility Name
Boehringer Ingelheim Investigational Site
City
Dnepropetrovsk
ZIP/Postal Code
49023
Country
Ukraine
Facility Name
Boehringer Ingelheim Investigational Site
City
Ivano-Frankovsk
ZIP/Postal Code
76000
Country
Ukraine
Facility Name
Boehringer Ingelheim Investigational Site
City
Kharkov
ZIP/Postal Code
61018
Country
Ukraine
Facility Name
Boehringer Ingelheim Investigational Site
City
Kharkov
ZIP/Postal Code
61037
Country
Ukraine
Facility Name
Boehringer Ingelheim Investigational Site
City
Kiev
ZIP/Postal Code
02175
Country
Ukraine
Facility Name
Boehringer Ingelheim Investigational Site
City
Kiev
ZIP/Postal Code
03151
Country
Ukraine
Facility Name
Boehringer Ingelheim Investigational Site
City
Kiev
ZIP/Postal Code
03680
Country
Ukraine
Facility Name
Boehringer Ingelheim Investigational Site
City
Kiev
ZIP/Postal Code
04114
Country
Ukraine
Facility Name
Boehringer Ingelheim Investigational Site
City
Lutsk
ZIP/Postal Code
43024
Country
Ukraine
Facility Name
Boehringer Ingelheim Investigational Site
City
Lvov
ZIP/Postal Code
73013
Country
Ukraine
Facility Name
Boehringer Ingelheim Investigational Site
City
Lvov
ZIP/Postal Code
79015
Country
Ukraine
Facility Name
Boehringer Ingelheim Investigational Site
City
Zaporozhye
ZIP/Postal Code
69035
Country
Ukraine

12. IPD Sharing Statement

Learn more about this trial

Combination of Telmisartan and Simvastatin in the Treatment of Hypertension and Hypercholesterolemia

We'll reach out to this number within 24 hrs